Outlook Therapeutics, Inc.
NASDAQ:OTLK · NASDAQ Capital Market
+$0.12 today
Vol 41.29M · Avg 15.13M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:OTLK · Revenue to Net Income
Key Ratios
Analysis
$333.1K of revenue converted into -$61.0M of net income for the selected period. Gross margin is 313.6% and net margin is 2889.6%, showing how much revenue survives after costs and taxes. EPS is $-1.62, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $756.3K +564.3% | $113.9K +157.7% | $44.2K -78.4% | $204.7K -21.9% | $262.1K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $657.2K +677.2% | -$113.9K -157.7% | -$44.2K +78.4% | -$204.7K +21.9% | -$262.1K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 46.5% | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $27.2T +65082964.0% | $41.8M +57.9% | $26.5M -37.5% | $42.3M +8.7% | $39.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $39.9M +33.4% | $29.9M +12.2% | $26.7M +28.6% | $20.7M +62.4% | $12.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $67.7M -5.6% | $71.7M +35.0% | $53.1M -15.5% | $62.9M +21.5% | $51.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $117.1K +2.8% | $113.9K +157.7% | $44.2K -78.4% | $204.7K -21.9% | $262.1K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$63.6M +11.8% | -$72.1M -25.7% | -$57.4M +10.8% | -$64.4M -24.9% | -$51.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -4497.7% | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$67.1M +6.5% | -$71.7M -35.0% | -$53.1M +15.8% | -$63.1M -21.9% | -$51.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -4744.3% | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $89.7K -90.1% | $906.1K | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $283.1K -91.0% | $3.2M +102.4% | $1.6M +4.9% | $1.5M +58.8% | $936.1K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $3.1M +184.3% | -$3.7M +37.5% | -$5.9M -96.5% | -$3.0M -107.6% | -$1.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$64.0M +15.1% | -$75.4M -27.8% | -$59.0M +10.7% | -$66.0M -24.2% | -$53.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -4526.0% | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$1.6M -55522.5% | $2.8K +0.0% | $2.8K +0.0% | $2.8K +40.0% | $2.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$62.4M +17.2% | -$75.4M -27.8% | -$59.0M +10.7% | -$66.1M -24.2% | -$53.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -4416.2% | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +55.9% | -$4 +14.0% | -$5 +24.2% | -$6 +10.5% | -$7 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +55.9% | -$4 +14.0% | -$5 +24.2% | -$6 +10.5% | -$7 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $34.8M +87.6% | $18.5M +48.3% | $12.5M +18.0% | $10.6M +38.9% | $7.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $25.5M +37.3% | $18.5M +48.3% | $12.5M +18.0% | $10.6M +38.9% | $7.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$194.78M
Equillium, Inc.
NASDAQ:EQ
$99.82M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
Cue Biopharma, Inc.
NASDAQ:CUE
$64.46M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
IO Biotech, Inc.
IOBT
$885,690.00
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OTLK generate?
Outlook Therapeutics, Inc. (OTLK) reported $1.41M of revenue in fiscal 2025.
Is OTLK profitable?
Outlook Therapeutics, Inc. (OTLK) reported -$62,424,863.00 of net income, with a net margin of -4416.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.